In This Article:
Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should the companies meet expectations. If a buoyant growth prospect is what you’re after in your next investment, I’ve put together a list of high-growth stocks you may be interested in, based on the latest financial data from each company.
BBI Life Sciences Corporation (SEHK:1035)
BBI Life Sciences Corporation, together with its subsidiaries, develops, manufactures, and sells various life sciences products used in scientific research in the People’s Republic of China, North America, South America, Europe, Africa, and internationally. Established in 2013, and run by CEO Luojia Wang, the company employs 1,208 people and with the market cap of HKD HK$1.58B, it falls under the small-cap group.
1035 is expected to deliver a buoyant earnings growth over the next couple of years of 21.54%, driven by a positive double-digit revenue growth of 48.58% and cost-cutting initiatives. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a positive return on equity of 11.90%. 1035 ticks the boxes for robust growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Considering 1035 as a potential investment? I recommend researching its fundamentals here.
China Medical System Holdings Limited (SEHK:867)
China Medical System Holdings Limited, an investment holding company, produces medicines; and markets, promotes, and sells drugs in the People’s Republic of China. Founded in 1995, and currently lead by Kong Lam, the company currently employs 3,600 people and has a market cap of HKD HK$39.20B, putting it in the large-cap group.
867’s projected future profit growth is a robust 17.26%, with an underlying 30.81% growth from its revenues expected over the upcoming years. It appears that 867’s profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 24.05%. 867’s impressive outlook on all aspects makes it a worthy company to spend more time to understand. Want to know more about 867? Check out its fundamental factors here.